Clinical Trials
5
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.
Phase 1
Active, not recruiting
- Conditions
- Healthy
- Interventions
- Drug: REM0045392Drug: Placebo
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- reMYND
- Target Recruit Count
- 52
- Registration Number
- NCT07016464
- Locations
- 🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit, Edegem, Belgium
A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- Drug: REM0046127 Low DoseDrug: PlaceboDrug: REM0046127 High Dose
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- reMYND
- Target Recruit Count
- 14
- Registration Number
- NCT05478031
- Locations
- 🇳🇱
BRC Amsterdam, Amsterdam, Netherlands
🇪🇸Fundacion ACE, Barcelona, Spain
🇪🇸FISEVI Hospital Universitario Virgen del Rocio, Sevilla, Spain
A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- reMYND
- Target Recruit Count
- 77
- Registration Number
- NCT04672135
- Locations
- 🇦🇹
Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria
News
Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership
Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.